BiCKI IL-7 / OSE Immunotherapeutics, Boehringer Ingelheim - LARVOL DELTA

OSE Immunotherapeutics Updates on its Research Programs in Presentations Selected for Upcoming International Conferences (Businesswire) - "OSE Immunotherapeutics SA...presents scientific updates in presentations selected for European and American conferences: at the 7th International Cancer Immunotherapy (CICON) Conference in Milan, Italy (September 20 – 23), at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA, US (November 1 – 5) and at the 15th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Lisbon, Portugal (November 14 – 16). The communications will feature the latest progress on the Company’s research programs in immuno-oncology, namely CLEC-1 (novel myeloid immune checkpoint), CYTOMASK, a new and innovative CIS-demasking cytokine linker technology, BiCKI^®-IL-7 (bifunctional therapy targeting PD-1 and IL-7), and Tedopi^® (T-cell epitope-based cancer vaccine)."

Clinical data • Oncology

OSE Immunotherapeutics Presents Update on BiCKI IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences (Businesswire) - "OSE Immunotherapeutics...presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands (June 7), at the FOCIS 2023 Annual Meeting (June 20-23), the 4th Annual Cytokine-Based Drug Development Summit 2023 (June 27-29) and at the 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 (July 18-20) in Boston, US. The communications feature the latest research on pre-IND programs for BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7), CLEC-1 (new myeloid immune checkpoint) in immuno-oncology and for OSE-230 (first pro-resolutive monoclonal antibody) in chronic inflammation."

Preclinical • Burkitt Lymphoma • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Immunology • Inflammation • Liver Cancer • Lung Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • Thoracic Cancer

OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio (Businesswire) - "The poster presentation concluded on the strong rationale that OSE-127 may represent a powerful novel immunotherapy option for ALL patients based on a unique dual mechanism of action. This antibody both blocks oncogenic interleukin-7 fuel pathway and simultaneously triggers macrophage-driven phagocytosis of leukemic cells....The presentation reports that anti-PD1/IL-7v BiCKI®-IL-7 showed significant monotherapy anti-tumor efficacy in different in vivo models. In addition, BiCKI®-IL-7 showed significant anti-tumor efficacy post-anti-PD-(L)1 failure in a preclinical model, highlighting the clinical potential of BiCKI®-IL-7v in immune checkpoint inhibitor resistant patients."

Preclinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology (Businesswire) - "OSE Immunotherapeutics SA...announced it will be presenting five posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting....Four communications will feature the latest research on pre-IND programs for the pioneering Myeloid and BiCKI^® platforms, namely presentations on CLEC-1 (new myeloid immune checkpoint) and BiCKI^®-IL7 (new bifunctional therapy targeting PD-1 and IL-7), and OSE-127 (anti-IL-7 receptor antagonist) hematology program. A fifth communication will feature biomarker analyses on BI 765063 (anti-SIRPα monoclonal antibody on CD47/SIRPα pathway) from the ongoing Phase 1 clinical trial in advanced solid tumors."

Biomarker • P1 data • Preclinical • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Solid Tumor

OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs (Businesswire) - "BiCKI^®-IL-7 program in Immuno-Oncology (SITC 2022)....The latest data presented at the SITC 2022 show high IL-7 receptor (IL-7R) pathway expression in TILs (Tumor-Infiltrating Lymphocytes) and tumor-specific T-cell clonotypes, predictive of long-term ICI (Immune Checkpoint Inhibitor) clinical responses. Reversely, decreased IL-7R pathway expression is associated with metabolic stress and apoptosis of tumor-specific T-cells. Redirecting IL-7 selectively on PD1 + T-cells provides stemness, proliferative and survival signals to tumor-specific T-cells inducing durable responses. Additional data presented provides a strong rationale for selective delivery of IL-7 to tumor-specific T-cells to sustain long-lasting preclinical response, as well as selective proliferation and survival of stem-like memory T-cells in vivo."

Preclinical • Oncology

OSE Immunotherapeutics Presents Update on BiCKI-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences (Businesswire) - "OSE Immunotherapeutics SA...announced that three posters have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting which will be held in person and virtually in Boston, MA, November 8 – 12. The posters will feature the latest preclinical data on the Company’s pioneering drug discovery BiCKI® and Myeloid platforms and including BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7) and CLEC-1 (new myeloid immune checkpoint). The Company was also invited for an oral presentation at the Macrophage-directed Therapies Summit of its CLEC-1 program (Boston, October 2022)."

Preclinical • Oncology

OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results (Businesswire) - "A newly formed SAB combining the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy...The SAB includes...Dr. Jennifer Wargo...."

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI-IL-7 Cancer Immunotherapy (GlobeNewswire) - "OSE Immunotherapeutics SA...announced that the Company is invited to present the latest progress on its bispecific antibody checkpoint inhibitor BiCKI® platform, and in particular on its bifunctional therapy targeting PD-1 and the Interleukin-7 (IL-7) cytokine, BiCKI®-IL-7, during a plenary oral presentation in an educational session dedicated to immunocytokines at the American Association Cancer for Research (AACR) annual meeting....This presentation highlights the differentiation of our novel bispecific therapy combining anti-PD1 and IL-7 cytokine and positions it as a high potential asset for cancer patients suffering from immune escape following checkpoint inhibitor treatments."

Preclinical • Oncology

OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment (GlobeNewswire) - "OSE Immunotherapeutics SA...today announces that the United States Patent and Trademark Office (USPTO) has issued a first notice of allowance for a patent application covering OSE-279, an anti-PD1 monoclonal antibody, and its use in cancer treatment. This patent will strengthen the global intellectual property of OSE-279 and will provide the product protection until 2039."

Patent • Oncology

OSE Immunotherapeutics Presented New Translational Data on Tedopi and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI-IL-7 (GlobeNewswire) - P3, N=363; ATALANTE 1 (NCT02654587); Sponsor: OSE Immunotherapeutics; "OSE Immunotherapeutics SA...presented new clinical and translational data on Tedopi® (neoepitope-based cancer vaccine) in non-small cell lung cancer and the latest data from BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7) preclinical programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington D.C. (and virtually) held on November 10 – 14, 2021...A high/high Immunoscore® associated with high CD8 T-cell tumor infiltration, and a higher proportion of CD8 cells interacting with PD-L1 cells in a patient with a partial response...monotherapy with BiCKI®-IL-7, an anti-PD1/IL-7 bifunctional monoclonal antibody, that induces long-term survival, proliferation and responses without signs of exhaustion of T cells as well as robust in vivo anti-tumor memory response in different preclinical models."

P3 data • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire) - "OSE Immunotherapeutics SA...announces that three abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington D.C. (and virtually) held on November 10 – 14, 2021. The three posters will include new clinical and translational data on Tedopi® (neoepitope-based cancer vaccine) in non-small cell lung cancer and the latest data on preclinical programs BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7) and CLEC-1 (new 'Don’t Eat Me' myeloid checkpoint target)."

P3 data • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

[VIRTUAL] Optimized antagonist anti-PD-1/IL-7 bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity (AACR 2021) - "Taken together, our data validate the therapeutic potential of providing IL-7 signal to strengthen PD1 therapy and prevent immunoresistance by sustaining T cell response and overcoming Treg suppression. The bispecific BiCKI®IL-7 mutein can preferentially deliver and activate IL-7 into PD1+ tumor-specific T cells limiting the risk of I-O/I-O immunotoxicity."

IO biomarker • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • CD8 • FCGR2A • FCGR2B • IFNG • IL15 • IL2 • IL7 • IL7R

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting (Businesswire) - "OSE Immunotherapeutics...announced today that new preclinical data has been selected for e-poster presentations at the American Association of Cancer Research (AACR) Virtual Annual Meeting I, to be held on April 10 - 15, 2021. The presentations will include data on the novel 'Don’t Eat Me' signal myeloid immune checkpoint target CLEC-1 (a C-type lectin receptor), BiCKI-IL-7 bifunctional therapy targeting PD-1...The combined research data collected to date validate the strong therapeutic potential of providing IL-7 signals to strengthen PD-1 therapy and prevent immuno-resistance by sustaining T cell response and overcoming Treg suppression."

Preclinical • Oncology